Massa I - Search Results

1

Uncovering the genomic heterogeneity of multifocal breast cancer.

Desmedt C, Fumagalli D, Pietri E, Zoppoli G, Brown D, Nik-Zainal S, Gundem G, Rothé F, Majjaj S, Garuti A, Carminati E, Loi S, Van Brussel T, Boeckx B, Maetens M, Mudie L, Vincent D, Kheddoumi N, Serra L, Massa I, Ballestrero A, Amadori D, Salgado R, de Wind A, Lambrechts D, Piccart M, Larsimont D, Campbell PJ, Sotiriou C. Desmedt C, et al. Among authors: massa i. J Pathol. 2015 Aug;236(4):457-66. doi: 10.1002/path.4540. Epub 2015 May 7. J Pathol. 2015. PMID: 25850943 Free PMC article.

2

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.

Passardi A, Massa I, Zoli W, Gianni L, Milandri C, Zumaglini F, Nanni O, Maltoni R, Frassineti GL, Amadori D. Passardi A, et al. Among authors: massa i. BMC Cancer. 2006 Mar 21;6:76. doi: 10.1186/1471-2407-6-76. BMC Cancer. 2006. PMID: 16551351 Free PMC article. Clinical Trial.

3

Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer.

Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, Storci G, Passardi A, Massa I, Ricci M, Gusolfino D, Fabbri F, Ulivi P, Brigliadori G, Amadori D, Bonafe M. Vannini I, et al. Among authors: massa i. Tumour Biol. 2008;29(3):145-51. doi: 10.1159/000143400. Epub 2008 Jul 9. Tumour Biol. 2008. PMID: 18612219

4

A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.

Rocca A, Maltoni R, Passardi A, Massa I, Aquilina M, Ridolfi R, Ibrahim T, Cecconetto L, Sarti S, Pietri E, Nanni O, Amadori D. Rocca A, et al. Among authors: massa i. Cancer Chemother Pharmacol. 2010 Apr;65(5):871-6. doi: 10.1007/s00280-009-1092-8. Epub 2009 Aug 20. Cancer Chemother Pharmacol. 2010. PMID: 19693503 Clinical Trial.

5

Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast.

Tumedei MM, Silvestrini R, Ravaioli S, Massa I, Maltoni R, Rocca A, Folli S, Buggi F, Curcio A, Serra L, Puccetti M, Amadori D, Bravaccini S. Tumedei MM, et al. Among authors: massa i. Int J Biol Markers. 2015 Nov 11;30(4):e425-8. doi: 10.5301/jbm.5000163. Int J Biol Markers. 2015. PMID: 26165687 Free article.

6

Androgen receptor signaling pathways as a target for breast cancer treatment.

Pietri E, Conteduca V, Andreis D, Massa I, Melegari E, Sarti S, Cecconetto L, Schirone A, Bravaccini S, Serra P, Fedeli A, Maltoni R, Amadori D, De Giorgi U, Rocca A. Pietri E, et al. Among authors: massa i. Endocr Relat Cancer. 2016 Oct;23(10):R485-98. doi: 10.1530/ERC-16-0190. Epub 2016 Aug 15. Endocr Relat Cancer. 2016. PMID: 27528625 Review.

7

The challenge of sustainability in healthcare systems: Frequency and cost of inappropriate patterns of breast cancer care (the E.Pic.A study).

Massa I, Balzi W, Burattini C, Gentili N, Bucchi L, Nanni O, Gallegati D, Pierini A, Amadori D, Falcini F, Altini M. Massa I, et al. Breast. 2017 Aug;34:103-107. doi: 10.1016/j.breast.2017.05.007. Epub 2017 May 27. Breast. 2017. PMID: 28558338

8

Quantification of dehydroepiandrosterone in human serum on a routine basis: development and validation of a tandem mass spectrometry method based on a surrogate analyte.

Campi B, Frascarelli S, Pietri E, Massa I, Donati C, Bozic R, Bertelloni S, Paolicchi A, Zucchi R, Saba A. Campi B, et al. Among authors: massa i. Anal Bioanal Chem. 2018 Jan;410(2):407-416. doi: 10.1007/s00216-017-0731-x. Epub 2017 Nov 6. Anal Bioanal Chem. 2018. PMID: 29110028

9

Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy.

Ravaioli S, Tumedei MM, Foca F, Maltoni R, Rocca A, Massa I, Pietri E, Bravaccini S. Ravaioli S, et al. Among authors: massa i. Int J Exp Pathol. 2017 Oct;98(5):289-295. doi: 10.1111/iep.12253. Epub 2017 Nov 28. Int J Exp Pathol. 2017. PMID: 29193395 Free PMC article.

10

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.

Pietri E, Massa I, Bravaccini S, Ravaioli S, Tumedei MM, Petracci E, Donati C, Schirone A, Piacentini F, Gianni L, Nicolini M, Campadelli E, Gennari A, Saba A, Campi B, Valmorri L, Andreis D, Fabbri F, Amadori D, Rocca A. Pietri E, et al. Among authors: massa i. Oncologist. 2019 Jun;24(6):743-e205. doi: 10.1634/theoncologist.2018-0243. Epub 2018 Dec 27. Oncologist. 2019. PMID: 30591548 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

218 results

Search Page